
HIBISCUS I/II
HICKORY
Remission
Endoscopic improvement
Placebo
95th perc. 6.68 μg/mL
50th perc. 3.65 μg/mL
5th perc. 1.43 μg/mL
95th perc. 12200 μg/g
5th perc. 142 μg/g
95th perc. 11 score
5th perc. 6 score
95th perc. 36.2 mg/L
5th perc. 0.312 mg/L
95th perc. 47 g/L
5th perc. 33 g/L
Previously smoked
Never smoked
Current smoker
Etrolizumab Ctrough
Baseline FeCal
MCS
Baseline CRP
Baseline Albumin
Smoking status
0
.2
.4
.6
.8
1
Positive outcome probability (90% CI)

Figure S2. Forest plots for all final models based on data from the induction phases of HIBISCUS I/HIBISCUS II and HICKORY. Diamonds and error bars depict the median and 90% confidence interval, respectively, for the outcome proportion derived from a 200-sample bootstrap per model. For each covariate/endpoint, the proportion is presented assuming typical values for all other covariates. A typical subject was treated with etrolizumab with a median exposure of 3.65 μg/mL at week 4 of induction, never smoked and had baseline levels for albumin, CRP, FeCal, and MCS score of 41 g/L, 4.2 mg/L, 1623 μg/g, and 9, respectively. perc: percentile; CRP: C-reactive protein; C_{trough}: trough concentration; FeCal: fecal calprotectin; MCS: Mayo Clinic Score.